ANNOUNCEMENT NO. 163 – 14 AUGUST 2025
HELLERUP, Denmark, Aug. 14, 2025 /PRNewswire/ -- Despite challenging market conditions, NORDEN delivered a net profit of USD...
COPENHAGEN, Denmark, Aug. 13, 2025 /PRNewswire/ -- For years, businesses have raced to shave milliseconds off page-load times. But a new global survey reveals a...
COPENHAGEN, Denmark, Aug. 13, 2025 /CNW/ -- For years, businesses have raced to shave milliseconds off page-load times. But a new global survey reveals a...
COPENHAGEN, Denmark, Aug. 12, 2025 /PRNewswire/ -- A field trial in Denmark shows Ambient Carbon's Methane Eradication Photochemical System (MEPS) eliminated up to 90%...
AARHUS, Denmark, Aug. 7, 2025 /PRNewswire/ -- Stibo Systems, a global master data management (MDM) solutions provider, has deepened its strategic collaboration with Microsoft,...
KONGENS LYNGBY, Denmark, Aug. 5, 2025 /PRNewswire/ -- Aquaporin has successfully completed the Living Lab Project to develop the world's first biomimetic low-energy Aquaporin...
KONGENS LYNGBY, Denmark, Aug. 5, 2025 /PRNewswire/ -- Aquaporin has successfully completed the Living Lab Project to develop the world's first biomimetic low-energy Aquaporin...
COPENHAGEN, Denmark, July 11, 2025 /PRNewswire/ -- The roll-up of Dutch payroll software company Employes marks Danish-founded Ageras' second acquisition this year and its...
COPENHAGEN, Denmark, June 25, 2025 /PRNewswire/ -- Designed proteins are anticipated to have groundbreaking impact on a range of issues from treating disease to...
COPENHAGEN, Denmark, June 25, 2025 /PRNewswire/ -- Designed proteins are anticipated to have groundbreaking impact on a range of issues from treating disease to...
Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2A phase II...
Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2A phase II...
The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...